Replies to post #75014 on Biotech Values

[DewDiligence]

MNTA – I don’t think the FDA’s non-action on Teva’s Citizen Petition for Copaxone was behind today’s stock move because the non-action letter is neutral for MNTA, not bullish. All the FDA has done is put off a decision on the CP until there’s an actual need for a decision to be made (i.e. after expiration of the automatic 30-month stay in early 2011).

[ThomasS]

MNTA/Teva: Teva Pharmaceutical-TEVA petition decline a negative, says Collins Stewart
Collins Stewart views the FDA's decision to decline review of Teva's Citizen Petition for Copaxone as an incremental negative for the company. The firm keeps a Hold rating on the stock.

{With everything Teva has going for it, I'd call this irrelevant.}